| [1] |
George JN, Nester CM. Syndromes of thrombotic microangiopathy [J]. N Engl J Med, 2014, 371(19): 1847-1848.
|
| [2] |
彭娜，佟芳. 非典型溶血尿毒综合征的研究进[J]. 临床肾脏病杂志，2018，18(6): 381-383.
|
| [3] |
Yoshida Y, Kato H, Ikeda Y, et al. Pathogenesis of atypical hemolytic uremic syndrome [J]. J Atheroscler Thromb, 2019, 26(2): 99-110.
|
| [4] |
Noris M, Remuzzi G. Atypical hemolytic uremic syndrome [J]. N Engl J Med, 2009, 361(17): 1676-1687.
|
| [5] |
Cataland SR, Wu HM. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies [J]. Eur J Intern Med, 2013, 24(6): 486-491.
|
| [6] |
Sawai T, Nangaku M, Ashida A, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society [J]. Clin Exp Nephrol, 2014, 18(1): 4-9.
|
| [7] |
Bhuyan UN. Thrombotic microangiopathy with hypertension and acute renal failure in children (a typical hemolytic uremic syndrome) [J]. J Postgrad Med, 1994, 40(3): 120-122.
|
| [8] |
Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome [J]. J Am Soc Nephrol, 2005, 16(7): 2150-2155.
|
| [9] |
Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome [J]. Blood, 2006, 108(4): 1267-1279.
|
| [10] |
Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome [J]. Blood, 2010, 115(2): 379-387.
|
| [11] |
de Jorge EG, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome [J]. Proc Natl Acad Sci USA, 2007, 104(1): 240-245.
|
| [12] |
Kato H, Nangaku M, Hataya H, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan[J]. Clin Exp Nephrol, 2016, 20(4): 536-543.
|
| [13] |
Nickavar A, Sotoudeh K. Assesment, treatment and prevention of atypical hemolytic uremic syndrome [J]. Int J Prev Med, 2013, 4(1): 6-14.
|
| [14] |
Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies [J]. Kidney Int, 2015, 87(5): 1061-1073.
|
| [15] |
Cao M, Leite BN, Ferreiro T, et al. Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury [J]. Am J Nephrol, 2018, 48(3): 225-233.
|